News
Common sleep aid could increase Alzheimer’s risk, study suggests

Deep sleep may wash away waste buildup in the brain during waking hours, an essential process for maintaining brain health, new research has found.
The findings also offer insights into how sleep aids may disrupt the “brainwashing” system, potentially affecting cognitive function in the long run.
Scientists have known that the brain has a built-in waste removal system, called the glymphatic system, which circulates fluid in the brain and spinal cord to clear out waste.
This process helps remove toxic proteins that form sticky plaques linked to neurological disorders.
However, what drives this system has remained unclear, until now.
Danish scientists found that a molecule called norepinephrine plays a key role in the brain’s cleaning in mice.
During deep sleep, the brainstem releases tiny waves of norepinephrine about once every 50 seconds.
Norepinephrine triggers blood vessels to contract, generating slow pulsations that create a rhythmic flow in the surrounding fluid to carry waste away.
Maiken Nedergaard of the University of Rochester and University of Copenhagen, Denmark, is senior author of the study.
Nedergaard said: “It’s like turning on the dishwasher before you go to bed and waking up with a clean brain.
“We’re essentially asking what drives this process and trying to define restorative sleep based on glymphatic clearance.”
To find clues, Nedergaard and her team looked into what happens in mice when the brain sleeps.
Specifically, they focused on the relationship between norepinephrine and blood flow during deep slumber.
They found that norepinephrine waves correlate to variations in brain blood volume, suggesting norepinephrine triggers a rhythmic pulsation in the blood vessels.
The team then compared the changes in blood volume to brain fluid flow.
They found that the brain fluid flow fluctuates in correspondence to blood volume changes, suggesting that the vessels act as pumps to propel the surrounding brain fluid to flush out waste.
Natalie Hauglund of the University of Copenhagen and the University of Oxford, UK, is the study’s lead author.
Hauglund said: “You can view norepinephrine as this conductor of an orchestra.
“There’s a harmony in the constriction and dilation of the arteries, which then drives the cerebrospinal fluid through the brain to remove the waste products.”
Hauglund then had another question—is all sleep created equal?
To find out, the researchers gave mice zolpidem, a common drug to aid sleep.
They found that the norepinephrine waves during deep sleep was 50 per cent lower in zolpidem-treated mice than in naturally sleeping mice.
Although the zolpidem-treated mice fell asleep faster, fluid transport into the brain dropped more than 30 per cent.
The findings suggest that the sleeping aid may disrupt the norepinephrine-driven waste clearance during sleep.
Hauglund said: “More and more people are using sleep medication, and it’s really important to know if that’s healthy sleep.
“If people aren’t getting the full benefits of sleep, they should be aware of that so they can make informed decisions.”
The team says that the findings likely apply to humans, who also have a glymphatic system, although this needs further testing.
Researchers have observed similar norepinephrine waves, blood flow patterns, and brain fluid flux in humans.
Their findings may offer insights into how poor sleep may contribute to neurological disorders like Alzheimer’s disease.
Nedergaard said: “Now we know norepinephrine is driving the cleaning of the brain, we may figure out how to get people a long and restorative sleep.”
News
Finding could help identify diabetes patients at risk of vascular damage

The longer someone has type 2 diabetes, the higher their cardiovascular disease risk, and changes in red blood cells may help explain it, new research suggests.
The study found red blood cells from patients with long-term diabetes harmed blood vessel function, while no such effect was seen in those newly diagnosed.
After seven years of follow-up, the blood cells of people initially diagnosed had developed the same harmful properties.
Zhichao Zhou, associate professor at Karolinska Institutet and lead author, said: “What really stands out in our study is that it is not only the presence of type 2 diabetes that matters, but how long you have had the disease.
“It is only after several years that red blood cells develop a harmful effect on blood vessels.”
Researchers at Karolinska Institutet in Sweden studied animals and patients with type 2 diabetes.
They identified microRNA-210, a small RNA that helps regulate gene activity, as a possible early biomarker of cardiovascular risk.
When its levels were restored in red blood cells, blood vessel function improved.
Eftychia Kontidou, doctoral student and first author, said: “If we can identify which patients are at greatest risk before vascular damage has already occurred, we can also become better at preventing complications.”
The researchers are now investigating whether the biomarker can be used in larger population studies.
News
Routine vaccines may protect against dementia, research finds

Routine vaccines for adults may reduce dementia risk, a review of more than 100 million people suggests.
The research found both flu and shingles vaccines were associated with a lower risk in adults aged 50 and over.
The shingles (herpes zoster) jab was linked to a 24 per cent lower risk of any dementia and a 47 per cent lower risk of Alzheimer’s disease.
A joint Italian-Canadian neuroscience review points to a pattern that public health experts say is hard to ignore, suggesting vaccines against common infections may offer long-term protection against the UK’s leading cause of death.
With an ageing population, about two million people are projected to be living with dementia in the UK by 2050.
Prof Sir Andrew Pollard is director of the Oxford Vaccine Group and former chair of the Joint Committee on Vaccination and Immunisation.
He said: “Vaccines for pneumonia, shingles, and influenza in older adults have been shown to reduce the risk of serious infections and hospitalisation caused by these diseases.
“But studies in the past few years have raised the intriguing possibility that vaccination could also provide a welcome reduction in the risk of dementia, a disease which places a huge burden on society and the NHS.”
A separate large-scale randomised trial in Wales compared shingles vaccines Zostavax and Shingrix to address the “healthy user effect”, where people who get vaccinated tend to be more health-conscious. As both groups were vaccinated, this helped control for that bias.
The results showed those receiving the newer Shingrix vaccine had a substantially lower risk of developing dementia over subsequent years.
Dr Maxime Taquet, clinical lecturer in psychiatry at Oxford, who led that study, said: “The size and nature of this study makes these findings convincing, and should motivate further research.”
Wellness
Food preservatives linked to increased diabetes and cancer risk, study finds
Insights4 weeks agoStudy links body image issues in adolescence to adult depression
News4 weeks agoCommonly-prescribed drugs liked to 50% increased risk of dementia
News4 weeks agoVaccine raises hope for million living with knee osteoarthritis
Insights3 weeks agoStudy reveals habits that could lower brain age by eight years
Research4 weeks agoExercise or risk ’10 years of ageing,’ weight loss jab users warned
News3 weeks agoConcurrent frailty and depression likely boost dementia risk in older people, study finds
Insights3 weeks agoLoss of confidence in midlife linked to dementia
News4 weeks agoSanofi and ADEL sign US$1.04bn Alzheimer’s deal





















